Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $27.00

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six research firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $27.00.

A number of equities analysts have weighed in on OLMA shares. JPMorgan Chase & Co. decreased their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Thursday, October 24th. Finally, Oppenheimer restated an "outperform" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently made changes to their positions in OLMA. China Universal Asset Management Co. Ltd. grew its stake in shares of Olema Pharmaceuticals by 67.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company's stock valued at $132,000 after acquiring an additional 4,442 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in Olema Pharmaceuticals by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 117,595 shares of the company's stock worth $1,404,000 after purchasing an additional 30,283 shares during the last quarter. SG Americas Securities LLC bought a new position in Olema Pharmaceuticals during the 3rd quarter worth approximately $156,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $145,000. Finally, Dana Investment Advisors Inc. acquired a new stake in Olema Pharmaceuticals in the 2nd quarter valued at $808,000. Institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Price Performance

OLMA traded up $0.09 during trading hours on Friday, reaching $11.62. The company's stock had a trading volume of 295,871 shares, compared to its average volume of 313,964. The stock has a market cap of $665.48 million, a PE ratio of -5.61 and a beta of 2.02. Olema Pharmaceuticals has a fifty-two week low of $8.51 and a fifty-two week high of $17.79. The business's 50-day moving average is $12.01 and its 200-day moving average is $11.86.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). Analysts expect that Olema Pharmaceuticals will post -1.51 EPS for the current year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.